By Dean Seal

Nuvation Bio said federal regulators have cleared an investigational new drug application for its treatment of advanced solid tumors, NUV-1511.

The biopharmaceutical company said Monday that the Food and Drug Administration's clearance makes NUV-1511 the first clinical candidate from the company's novel drug-drug conjugate platform.

"This IND clearance expands our clinical pipeline and validates the approach of our proprietary DDC platform to design potent oncology-focused chimeric small molecules which combine tumor-targeting specificity with the anti-cancer activity of known oncology agents," Chief Executive David Hung said.

The company said it expects to launch a Phase 1/2 study of NUV-1511 in the first half of this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

January 08, 2024 16:43 ET (21:43 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Panacea Acquisition
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Panacea Acquisition